Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma

Yasuhiro Fujisawa(University of Tsukuba), Norito Katoh(Kyoto Prefectural University of Medicine), Akiko Kishi(International Research Center for Japanese Studies), Satoshi Fukushima(Niigata Cancer Center Hospital), Manabu Fujimoto(The University of Osaka), Daisuke Yamada(International Research Center for Japanese Studies), Naohito Hatta(Toyama Prefectural Central Hospital), Naoki Noma(International Research Center for Japanese Studies), Susumu Fujiwara(International Research Center for Japanese Studies), Naoki Murao(Tonan Hospital), Taku Fujimura(Université Paris Cité), Akane Minagawa(Ōtani University), Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Junji Kato(Sapporo Medical University), Yoshiyuki Nakamura(University of Tsukuba), Jiro Uehara(Asahikawa Medical University), Tatsuya Takenouchi(Niigata Cancer Center Hospital), Dai Ogata(Unknown), Toshiharu Fujiyama(International Research Center for Japanese Studies), Kazuyasu Fujii(Kindai University Hospital), Toshihiko Hoashi(International Research Center for Japanese Studies), Manabu Yoshioka(International Research Center for Japanese Studies), Hironobu Ihn(Kumamoto University), Kenji Yokota(International Research Center for Japanese Studies), Yasuhiro Nakamura(University of Tsukuba), Tatsuya Kaji(Okayama University), Masashi Ishikawa(International Research Center for Japanese Studies), Yoshitsugu Shibayama(Fukuoka University), Takatoshi Shimiauchi(Hamamatsu University School of Medicine), Kanako Matsuyama(International Research Center for Japanese Studies), Jun Asai(Kyoto Prefectural University of Medicine), Shusuke Yoshikawa(Kyushu University), Hiroshi Uchi(Kyushu University)
Cancer Medicine
April 1, 2019
10.1002/cam4.2110
Cited by 111

Related Papers

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338
Accuracy in melanoma detection: A 10-year multicenter survey
|Journal of the American Academy of Dermatology|2011|206
Topical Simvastatin Accelerates Wound Healing in Diabetes by Enhancing Angiogenesis and Lymphangiogenesis
|American Journal Of Pathology|2012|166